AI literacy for healthcare executives does not mean understanding how neural networks work. It means being able to interrogate any AI deal with a small set of questions: what problem it solves, whether it works on your patients, who acts on its output, what happens when it fails, and how you will know. Leaders who ask these consistently make better decisions than technical enthusiasts.
A hospital board is shown a slide. The vendor’s sepsis prediction tool, the slide says, has an area under the curve of 0.8. A few board members nod. Nobody asks what that number means, where it was measured, or what the nurses will be expected to do when the alert fires. The contract is approved.
This is not a hypothetical failure mode. In 2021, researchers at Michigan Medicine published an external validation of a widely used proprietary sepsis model in JAMA Internal Medicine. In their hospital, it achieved an area under the curve of 0.63, well below the figures quoted in the developer’s own documentation, and it missed about two-thirds of the patients who developed sepsis. The model had been deployed at many hospitals before anyone checked it independently.
The executives who approved those deployments were not stupid. They lacked a habit of asking the few questions that would have exposed the gap between a vendor’s number and a hospital’s reality.
The thesis of this piece is that executive AI literacy is a questioning discipline, not a technical education. A chief executive does not need to know what a transformer is. They need five questions, asked every time, and the confidence to delay a decision until the answers are good.
What does AI literacy mean for healthcare leaders?
The phrase now has legal weight in some places. Article 4 of the European Union’s AI Act, which has applied since 2 February 2025, requires providers and deployers of AI systems to take measures to ensure a sufficient level of AI literacy among their staff and others using AI on their behalf. Hospitals deploying AI in the EU are deployers. National supervision and enforcement of these rules is due to begin in August 2026.
In the United States, the Joint Commission and the Coalition for Health AI released guidance on the responsible use of AI in healthcare in September 2025. It sets out seven elements, including governance structures, local validation, ongoing quality monitoring and education and training for staff who use AI tools.
Neither framework asks executives to become engineers. Both assume leaders can govern what they buy, which means understanding enough to ask the right questions and to recognize a weak answer. That is the kind of literacy that matters in a boardroom, and it is closer to financial literacy than to computer science. A board member does not need to be an accountant to ask where the cash is coming from.
Question 1: What problem does this solve, and how big is it?
Every AI proposal should start with a named operational or clinical problem, measured before the purchase.
“Improving sepsis care” is not a problem statement. “Our median time from sepsis criteria to antibiotics on medical wards is X hours, and our target is Y” is. Without a baseline, there is no way to tell later whether the tool helped, and every tool will be declared a success by the team that championed it.
A good answer includes the size of the problem, the current performance, and the target. A weak answer describes the technology’s capabilities and leaves the problem vague.
Question 2: Has it been shown to work on patients like ours?
Performance measured on the developer’s data, or at a prestigious academic center, may not transfer. Populations differ, documentation habits differ, equipment differs. The sepsis model validation is the textbook example of what happens when this question is skipped.
The Joint Commission and CHAI guidance explicitly recommends local validation and requesting validation data from vendors. Executives do not need to run the statistics. They need to ask: where was this tested, on how many patients like ours, with what result, and will we test it on our own data before it goes live?
A good answer offers external validation and a plan for a local silent trial, where the model runs in the background and its predictions are compared with what actually happened before anyone acts on them. A weak answer cites only the developer’s own performance figures.
Question 3: Who will act on the output, and what will they stop doing?
An AI tool is only as useful as the action it triggers. A prediction nobody acts on is a cost. A prediction that triggers action from an already overloaded team displaces other work, which may be more important.
This is where many projects fail quietly. A deterioration alert that goes to a ward nurse who already has too many patients adds an interruption. An inbox triage tool that routes messages to a pool with no extra staff does not reduce the pile, it reorders it.
Ask the proposer to name the role that acts on each output, the expected number of outputs per shift, and what that person will stop doing to make room. If nobody can answer, the project is a technology purchase without a workflow. Our earlier piece on the questions hospitals ask too late when buying digital health makes the same point about digital tools in general.
Question 4: What happens when it is wrong, or stops working?
Every model makes errors, and every system fails sometimes. Executives should ask about both.
For errors: what kinds of mistakes does this tool make, and who is harmed by them? A false alarm costs staff time and can cause alert fatigue. A missed case can cost a life. Tools can also perform worse for some patient groups, a risk that requires specific testing rather than assumptions.
For failure: what is the fallback if the vendor’s system goes down, the model drifts, or the company is acquired or goes bankrupt? Who owns the data and the configuration? How much notice will the vendor give before changing the model, and will the hospital be told?
A good answer includes a named clinical safety owner, an outage procedure, contractual notice of model updates and a clear route to switch the tool off. A weak answer assumes the tool will keep working as demonstrated.
Question 5: How will we know if it is working in six months?
This is the question most boards never ask, because it is asked after the purchase, when attention has moved on.
Before approval, agree two or three measures that will be reported back: the operational or clinical outcome from question 1, a measure of harm or error, and a measure of use, such as how often clinicians accept or override the tool. Set a review date, and a threshold at which the tool will be modified or withdrawn.
Monitoring is one of the seven elements in the Joint Commission and CHAI guidance, and for good reason. Models drift as patient populations and practices change. A tool that worked at launch can degrade silently.
A worked example: the board meeting, replayed
Replay the hypothetical board meeting with the five questions.
The vendor presents the sepsis tool. The chief executive asks what problem it solves. The chief medical officer answers: time to antibiotics on medical wards, currently averaging well above the hospital’s target, with a documented baseline.
Has it worked on patients like ours? The vendor has published validation at two academic centers, but none in a community hospital with a similar case mix. The board makes approval conditional on a three-month silent trial on the hospital’s own data.
Who acts on it? A rapid response nurse, not ward nurses, will receive alerts. The expected rate is estimated from the silent trial. The rapid response team will need additional hours, which are costed into the proposal.
What happens when it is wrong or down? The clinical safety officer owns incident review; the contract requires notice before model changes; the ward’s existing sepsis screening continues unchanged as the fallback.
How will we know? Time to antibiotics, alert volume, override rate and a count of missed sepsis cases found on chart review, reported to the quality committee at three and six months.
The meeting takes twenty minutes longer. The decision is far better. And if the silent trial showed performance like the Michigan validation, the hospital would find out before patients relied on it.
Isn’t this too simple for complex AI systems?
The strongest objection is that five questions cannot capture the real risks of modern AI, particularly generative models whose behavior is harder to characterize than a single risk score. Leaders who rely on a checklist may develop false confidence, and technical risks such as data leakage, prompt injection or subtle bias need specialist review.
That is true, and the questions are not a substitute for technical governance. A hospital using AI at scale needs a governance committee with clinical informatics, data science, legal, privacy and security expertise. The Joint Commission and CHAI guidance explicitly calls for this.
But the objection misreads the executive role. The board’s job is not to do the technical review. It is to insist that one has been done, to understand the answers well enough to spot evasion, and to hold someone accountable for outcomes. As we argued in our piece on the boardroom translation problem, the gap in most hospitals is not expertise but translation between the people who have it and the people who decide.
What this means for boards, executives and AI teams
For boards, make the five questions a standing requirement for any AI proposal above a set value or risk level, and ask for the six-month review in the minutes at the time of approval.
For executives, invest in a small internal capability that can answer questions 2 and 5 independently of vendors: someone who can run a silent trial and a monitoring dashboard. It is cheaper than one failed deployment.
For clinical and AI teams, bring answers to the five questions to every proposal. Projects that arrive with a baseline, a local validation plan, a named workflow owner, a fallback and a monitoring plan get approved faster and survive longer.
For EU-based organizations, Article 4 makes staff AI literacy a legal duty, not a nice-to-have. A documented, role-appropriate training approach for leaders and users is a practical way to meet it.
Frequently asked questions
What should healthcare executives know about AI?
Executives do not need technical expertise in machine learning. They need to be able to ask what problem a tool solves, whether it works on their own patients, who acts on its outputs, what happens when it fails, and how success will be measured. Consistently demanding good answers to these questions is the core of executive AI literacy.
Is AI literacy a legal requirement for hospitals?
In the European Union, yes. Article 4 of the AI Act, applicable since 2 February 2025, requires providers and deployers of AI systems to ensure sufficient AI literacy among staff who operate or use them. Supervision and enforcement are due to start in August 2026. Other jurisdictions rely more on accreditation and guidance than on explicit literacy laws.
What is the Joint Commission and CHAI AI guidance?
Released in September 2025 by the Joint Commission and the Coalition for Health AI, the guidance on responsible use of AI in healthcare sets out seven elements for health systems: governance, data security, privacy and transparency, education and training, quality monitoring, local validation, and risk and bias management. It is intended to support safe adoption at scale.
Why do hospital AI projects fail?
Common reasons include no measured baseline problem, performance that does not transfer from the developer’s data to local patients, no clear owner of the actions the tool triggers, and no monitoring after launch. The 2021 external validation of a widely used sepsis model, which found much weaker performance than reported, showed the cost of skipping local testing.
What is a silent trial for AI?
A silent trial runs an AI model on live local data without showing its outputs to clinicians, then compares its predictions with what actually happened. It reveals local performance, alert volumes and failure patterns before patients or staff depend on the tool, and gives executives evidence to decide whether to proceed.
The most dangerous person in an AI procurement is not the skeptic. It is the executive who is impressed by a number and does not ask where it came from.
Which of these five questions does your board skip most often, and what would it take to make it routine?
